Apogee Secures $403M Equity Raise, Extends Runway to 2029, Advances Lead Drug to Phase 3
Summary
Apogee Therapeutics announced the successful completion of an upsized public equity offering, raising approximately $403 million in gross proceeds. This significant capital infusion boosts the company's cash position to $1.3 billion, extending its operational runway into 2029, well past the planned Biologics License Application (BLA) filing for atopic dermatitis. The company also provided positive pipeline updates, confirming plans to initiate Phase 3 trials for its lead candidate, zumilokibart, in atopic dermatitis later this year, following strong 52-week Phase 2 Part A data. This material financing event de-risks the company's ability to fund critical clinical development programs. Traders should monitor the upcoming Q2 2026 readout of APEX Phase 2 Part B data and the initiation of Phase 3 trials in the second half of 2026 as key catalysts.
At the time of this announcement, APGE was trading at $82.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $34.34 to $95.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.